PTAB Institutes Review of Biogen’s Rituximab Patent

The PTAB has granted Celltrion’s petition for inter partes review of Biogen’s U.S. Patent 7,820,161.  (IPR2016-01614)  The patent is drawn to methods of treating rheumatoid arthritis by administration of rituximab.  Rituximab is sold by Biogen and Genentech under the trade-name Rituxan®.  Rituxan is FDA approved to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

This institution decision is posted along with other important IPR filings on biologic patents on our IPR tracker page.

Download PDF